# Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

> **NCT02201524** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 59 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** PF-04965842
- **DRUG:** PF-04965842
- **DRUG:** PF-04965842
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02201524
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 59 (ACTUAL)
- **Why stopped:** Study terminated 26 June 2015 due to changes in the drug development portfolio. This study was not terminated for reasons of safety and/or efficacy
- **Last updated:** 2016-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02201524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02201524, "Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02201524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*